{"id":294355,"date":"2026-10-08T11:36:51","date_gmt":"2026-10-08T06:06:51","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=294355"},"modified":"2026-10-08T11:36:51","modified_gmt":"2026-10-08T06:06:51","slug":"pharma-cdmo-and-distribution-stocks-strong-roadmap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-cdmo-and-distribution-stocks-strong-roadmap\/","title":{"rendered":"3 Pharma Cdmo and Distribution Stocks With a Strong Future Roadmap: Innova Captab, Entero Healthcare Solutions and Alembic Pharmaceuticals"},"content":{"rendered":"

Innova Captab Rs 1,166.20, P\/E 43.32. Entero Healthcare Rs 1,713.30, P\/E 44.49. Alembic Rs 833.80, P\/E 23.75. Closing prices of 7 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Pharma CDMO and distribution stocks with the clearest long-term roadmaps today include Innova Captab in contract manufacturing of pharma formulations and branded generics, Entero Healthcare Solutions in healthcare product distribution and pharmacies and Alembic Pharmaceuticals in branded generics and active ingredients. FY26 revenue growth was 30.4% at Innova Captab, 28.7% at Entero Healthcare and 10.2% at Alembic. P\/E stands at 43.32 for Innova Captab (industry 37.76), 44.49 for Entero Healthcare (industry 37.76) and 23.75 for Alembic (industry 37.76). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Pharma CDMO and distribution stocks give investors exposure to contract drug makers, healthcare distributors and a branded generics maker. Results depend on customer orders, product launches and working capital, which is why margins and cash flow matter as much as headline growth.<\/p>\n

This list covers three branded generic and distribution stocks: Innova Captab for contract manufacturing of pharma formulations and branded generics, Entero Healthcare Solutions for healthcare product distribution and pharmacies and Alembic Pharmaceuticals for branded generics and active ingredients. Every figure comes from the latest reported financials and the 7 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n